BR112012003232A2 - "uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos" - Google Patents
"uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos"Info
- Publication number
- BR112012003232A2 BR112012003232A2 BR112012003232A BR112012003232A BR112012003232A2 BR 112012003232 A2 BR112012003232 A2 BR 112012003232A2 BR 112012003232 A BR112012003232 A BR 112012003232A BR 112012003232 A BR112012003232 A BR 112012003232A BR 112012003232 A2 BR112012003232 A2 BR 112012003232A2
- Authority
- BR
- Brazil
- Prior art keywords
- gdf
- traps
- blood cell
- combined use
- increase blood
- Prior art date
Links
- 108010075944 Erythropoietin Receptors Proteins 0.000 title 1
- 102100036509 Erythropoietin receptor Human genes 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 210000000601 blood cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/583,177 US8058229B2 (en) | 2008-08-14 | 2009-08-13 | Method of increasing red blood cell levels or treating anemia in a patient |
US12/583.177 | 2009-08-13 | ||
PCT/US2009/004659 WO2010019261A1 (en) | 2008-08-14 | 2009-08-13 | Use of gdf traps to increase red blood cell levels |
USPCT/US2009/004659 | 2009-08-13 | ||
US30590110P | 2010-02-18 | 2010-02-18 | |
US61/305.901 | 2010-02-18 | ||
PCT/US2010/045509 WO2011020045A1 (en) | 2009-08-13 | 2010-08-13 | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012003232A2 true BR112012003232A2 (pt) | 2016-11-22 |
BR112012003232B1 BR112012003232B1 (pt) | 2022-02-22 |
Family
ID=43586530
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012003232-1A BR112012003232B1 (pt) | 2009-08-13 | 2010-08-13 | Uso de um polipeptídeo em conjunto com um ativador do receptor de eritropoetina para aumentar os níveis de célula vermelha no sangue ou tratar anemia |
BR122020019169-4A BR122020019169B1 (pt) | 2009-08-13 | 2010-08-13 | Polipeptídeo |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020019169-4A BR122020019169B1 (pt) | 2009-08-13 | 2010-08-13 | Polipeptídeo |
Country Status (14)
Country | Link |
---|---|
EP (3) | EP3838919A1 (pt) |
JP (4) | JP5909446B2 (pt) |
KR (5) | KR101882521B1 (pt) |
CN (7) | CN113082194A (pt) |
AU (1) | AU2010282361B2 (pt) |
BR (2) | BR112012003232B1 (pt) |
CA (1) | CA2770822C (pt) |
ES (2) | ES2844123T3 (pt) |
HK (2) | HK1223818A1 (pt) |
IL (6) | IL287990B (pt) |
MX (2) | MX2012001916A (pt) |
NZ (3) | NZ623113A (pt) |
RU (2) | RU2642302C1 (pt) |
WO (1) | WO2011020045A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
EP2111229B1 (en) | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EP2120999B1 (en) | 2007-02-09 | 2012-08-29 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | METHODS FOR INCREASING ADIPONECTIN |
BRPI1010587A2 (pt) | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
EP2440577A4 (en) * | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | Actriia結合剤およびその使用 |
BR122019023166B1 (pt) * | 2011-10-17 | 2021-02-23 | Acceleron Pharma, Inc | Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose |
US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
WO2014066486A2 (en) * | 2012-10-24 | 2014-05-01 | Celgene Corporation | Biomarker for use in treating anemia |
NZ747350A (en) * | 2012-10-24 | 2020-07-31 | Celgene Corp | Methods for treating anemia |
MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
WO2016069925A1 (en) | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
AU2015358469B2 (en) * | 2014-12-03 | 2021-05-27 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for treating anemia |
WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
EP3878857A1 (en) | 2015-04-22 | 2021-09-15 | Biogen MA Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
WO2016187378A1 (en) * | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
WO2017079591A2 (en) * | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
CN109311998A (zh) * | 2016-02-22 | 2019-02-05 | 阿塞勒隆制药公司 | 用于增加免疫活性的ActRII拮抗剂 |
PL3496739T3 (pl) | 2016-07-15 | 2021-10-11 | Acceleron Pharma Inc. | Kompozycje zawierające polipeptydy actriia do stosowania w leczeniu nadciśnienia płucnego |
MX2019001043A (es) * | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
AU2017338916B2 (en) * | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
EP3522934A4 (en) | 2016-10-05 | 2020-04-15 | Acceleron Pharma Inc. | COMPOSITIONS AND METHOD FOR THE TREATMENT OF RENOPATHY |
EP3538128A4 (en) | 2016-11-10 | 2020-07-22 | Keros Therapeutics, Inc. | ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE |
CN111050770A (zh) | 2017-06-14 | 2020-04-21 | 细胞基因公司 | 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法 |
CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
CA3087008A1 (en) | 2018-01-12 | 2019-07-18 | Keros Therapeutics, Inc. | Activin receptor type iib variants and methods of use thereof |
CA3098679A1 (en) * | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
US20210085710A1 (en) * | 2018-12-10 | 2021-03-25 | Elena Valentinovna ARSHINTSEVA | A new use of the poloxamer as a pharmacologically active substance |
CN111466337B (zh) * | 2020-05-19 | 2022-04-19 | 山东大学齐鲁医院 | 一种腹主动脉瘤动物模型及其构建方法 |
CN115317589A (zh) * | 2022-09-05 | 2022-11-11 | 中国海洋大学 | 脯氨酰羟化酶抑制剂及其应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
JPH11502717A (ja) | 1995-04-11 | 1999-03-09 | ザ ジェネラル ホスピタル コーポレーション | 逆ツーハイブリッドシステム |
AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
ATE291436T2 (de) * | 2000-05-15 | 2005-04-15 | Hoffmann La Roche | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
CA3094774A1 (en) * | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Use of hif prolyl hydroxylase inhibitors for treating neurological disorders |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
AP2005003367A0 (en) * | 2003-02-07 | 2005-09-30 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis. |
GB0304424D0 (en) * | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US20070003576A1 (en) * | 2004-12-09 | 2007-01-04 | Andrea Gambotto | Vaccines for the rapid response to pandemic avian influenza |
WO2006115274A1 (ja) * | 2005-04-26 | 2006-11-02 | Ajinomoto Co., Inc. | 骨髄赤血球前駆細胞分化促進剤 |
ES2370040T3 (es) * | 2005-10-07 | 2011-12-12 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Vacuna de metaloproteinasa 11 de la matriz. |
US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
WO2008073292A2 (en) * | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
CN105582521A (zh) * | 2006-12-18 | 2016-05-18 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
TWI548647B (zh) * | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
JP5773868B2 (ja) * | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ, インコーポレイテッド | アクチビン−ActRIIaのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
LT3750552T (lt) * | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
-
2010
- 2010-08-13 RU RU2016123808A patent/RU2642302C1/ru active
- 2010-08-13 EP EP20197940.8A patent/EP3838919A1/en not_active Withdrawn
- 2010-08-13 CA CA2770822A patent/CA2770822C/en active Active
- 2010-08-13 RU RU2012109393/10A patent/RU2592670C2/ru active
- 2010-08-13 NZ NZ623113A patent/NZ623113A/en unknown
- 2010-08-13 CN CN202110417494.3A patent/CN113082194A/zh active Pending
- 2010-08-13 EP EP16186033.3A patent/EP3117829B1/en active Active
- 2010-08-13 CN CN201510979490.9A patent/CN105535938B/zh active Active
- 2010-08-13 BR BR112012003232-1A patent/BR112012003232B1/pt active IP Right Grant
- 2010-08-13 KR KR1020127004678A patent/KR101882521B1/ko active IP Right Grant
- 2010-08-13 EP EP10808838.6A patent/EP2464369B1/en active Active
- 2010-08-13 CN CN202110879546.9A patent/CN113577291A/zh active Pending
- 2010-08-13 WO PCT/US2010/045509 patent/WO2011020045A1/en active Application Filing
- 2010-08-13 CN CN201510979291.8A patent/CN105412908B/zh active Active
- 2010-08-13 AU AU2010282361A patent/AU2010282361B2/en active Active
- 2010-08-13 ES ES16186033T patent/ES2844123T3/es active Active
- 2010-08-13 CN CN202110421547.9A patent/CN113171442A/zh active Pending
- 2010-08-13 KR KR1020207030283A patent/KR20200124322A/ko not_active Application Discontinuation
- 2010-08-13 BR BR122020019169-4A patent/BR122020019169B1/pt active IP Right Grant
- 2010-08-13 NZ NZ712943A patent/NZ712943A/en unknown
- 2010-08-13 ES ES10808838T patent/ES2796121T3/es active Active
- 2010-08-13 IL IL287990A patent/IL287990B/en unknown
- 2010-08-13 MX MX2012001916A patent/MX2012001916A/es active IP Right Grant
- 2010-08-13 NZ NZ598348A patent/NZ598348A/en unknown
- 2010-08-13 CN CN201080045618.XA patent/CN102655872B/zh active Active
- 2010-08-13 KR KR1020227045338A patent/KR102606494B1/ko active IP Right Grant
- 2010-08-13 KR KR1020197027722A patent/KR102170682B1/ko active IP Right Grant
- 2010-08-13 CN CN201510979350.1A patent/CN105561295B/zh active Active
- 2010-08-13 KR KR1020187020803A patent/KR20180085825A/ko active Application Filing
- 2010-08-13 JP JP2012524910A patent/JP5909446B2/ja active Active
-
2012
- 2012-02-12 IL IL218052A patent/IL218052A/en active IP Right Grant
- 2012-02-13 MX MX2019010341A patent/MX2019010341A/es unknown
-
2015
- 2015-12-03 JP JP2015236828A patent/JP2016034981A/ja not_active Withdrawn
-
2016
- 2016-09-09 HK HK16110720.8A patent/HK1223818A1/zh unknown
- 2016-11-01 HK HK16112523.3A patent/HK1224199A1/zh unknown
-
2017
- 2017-05-01 IL IL252045A patent/IL252045B/en active IP Right Grant
- 2017-05-01 IL IL25204417A patent/IL252044B/en active IP Right Grant
- 2017-05-01 IL IL252046A patent/IL252046B/en active IP Right Grant
-
2018
- 2018-08-17 JP JP2018153528A patent/JP6860533B2/ja active Active
-
2020
- 2020-07-05 IL IL275851A patent/IL275851B/en unknown
- 2020-09-29 JP JP2020163806A patent/JP2020203953A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012003232A2 (pt) | "uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos" | |
BRPI0919531A2 (pt) | anticorpos contra il17 humana e usos dos mesmos | |
BR112013014231A2 (pt) | composição de higiene pessoal e uso da composição de higiene pessoal | |
BRPI1011655A2 (pt) | uso de lcat para tratar anemia e disfunção de glóbulos vermelhos | |
BRPI0910852A2 (pt) | composições contendo lipídios e métodos de uso das mesmas | |
BRPI0813105A2 (pt) | Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo | |
BRPI1011876A2 (pt) | "composição farmacêutica estável e métodos de uso da mesma" | |
BR112012002331A2 (pt) | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica | |
EP2340031A4 (en) | USE OF SFM TRAPS TO INCREASE ERYTHROCYTE RATES | |
BRPI0813000A2 (pt) | Composições terapêuticas e uso das mesmas | |
BRPI0807612A2 (pt) | Marcadores metabólicos de condições diabéticas e métodos de uso do mesmo | |
BRPI0819971A2 (pt) | anticorpos contra vírus influenza e métodos de seu uso | |
BRPI0817879A2 (pt) | Composições e métodos de uso de anticorpos contra esclerostina | |
BRPI0812954A2 (pt) | Composição herbicidamente ativa, método para controlar vegetação indesejada, e, uso de composições | |
BRPI0811871A2 (pt) | Composições agroquímicas ácidas bioativas e uso das mesmas | |
BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
BRPI1014544A2 (pt) | anticorpors anti-il-17f e metodos de uso dos mesmos | |
BRPI0913656A2 (pt) | anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos | |
BR112013014235A2 (pt) | anticorpos anti-ccr4 e usos dos mesmos | |
BRPI0809342A2 (pt) | Eletrodos de bateria e baterias incluindo os referidos eletrodos | |
BRPI0924225A2 (pt) | linhagens de células que expressam nav e métodos de uso | |
DK2557924T3 (da) | Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse | |
BRPI0920355A2 (pt) | composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |